Cogstates

CogStates is a private, European technology company headquartered in Zurich, Switzerland, that specializes in computerized cognitive assessment tools and research platforms. Founded in 2001 by Peter R. Lezak, the company has positioned itself as a leading provider of scalable, clinically validated neuropsychological tests, targeting academic institutions, pharmaceutical and biotechnology companies, and clinical practice. Its flagship product suite, CogState Digital Neurotools, includes brief, automated tests measuring attention, working memory, executive function and processing speed. The tests are administered via tablet or computer and produce psychometric data that can be stored, analyzed and shared through a secure, cloud‑based platform.

CogState’s methodology is based on psychometric research and has been used in a wide range of clinical studies, particularly for monitoring cognitive side effects of chemotherapy, tracking disease progression in Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions, and evaluating the safety and efficacy of new therapeutics. The company partners with over 11,000 institutions worldwide and integrates its data into large clinical trial management systems. Its platform is designed to be language‑agnostic, with translations into more than 30 languages, facilitating global research efforts.

In addition to product sales, CogState offers research services, including data management, statistical support and software development, which aim to streamline neuropsychological testing for investigators. The company maintains compliance with FDA 21 CFR Part 11 and ISO 27001 standards, underscoring its commitment to data security and integrity. With a focus on digital innovation and evidence‑based cognitive assessment, CogState seeks to advance clinical practice and research by providing reliable, high‑throughput measurement of cognitive function.